Tania T. Dempsey, MD
Tania T. Dempsey, MD, is a world-renowned expert in complex, multisystem diseases. Her extensive knowledge and experience with mast cell activation syndrome (MCAS), mold, environmental toxins, Lyme disease, and vector-borne diseases have propelled her to the forefront of the international medical community as a recognized and trusted speaker, researcher, and physician. Dr. Dempsey is board-certified in Internal Medicine and Integrative and Holistic Medicine. She received her MD from The Johns Hopkins University School of Medicine and her BS from Cornell University, and completed her Internal Medicine residency at NYU Medical Center.
Dr. Dempsey founded AIM Center for Personalized Medicine in 2011, a destination practice in Purchase, New York, focused on complex, multisystem disorders. She is a founding member and Treasurer of the newly created nonprofit International Society for Mast Cell Activation Syndromes (ISMCAS) and serves as Secretary on the Board of Directors of the International Lyme and Associated Diseases Society (ILADS). She hosts the podcast Mast Cell Matters, where she takes deep dives into all things MCAS-related.
Dr. Dempsey is an accomplished international speaker, writer, and thought leader. She is well published in the medical literature and co-authored the chapter “Urogynecology and Hypermobility” in the 2020 book Disjointed: Navigating the Diagnosis and Management of hypermobile Ehlers-Danlos Syndrome and Hypermobility Spectrum Disorders. She was involved in a research study in collaboration with the TILT team at the University of Texas Health Science Center at San Antonio, which led to two publications: Mast cell activation may explain many cases of chemical intolerance (2021) and Chemical Intolerance and Mast Cell Activation: A Suspicious Synchronicity (2023).
She is also a co-author of several groundbreaking papers, including Diagnosis of mast cell activation syndrome: a global “consensus-2”, Learned cautions regarding antibody testing in mast cell activation syndrome, and Utility of glucagon-like-peptide-1-receptor agonists in mast cell activation syndrome. Her most recent publication is a follow-up to the original Consensus-2 paper, Progress in mast cell activation syndrome: the global consensus-2 diagnostic criteria at six years.